Last reviewed 2026-04-19 · How we verify

Hodgkin's disease

Approved treatments

• Oncovin · University of Colorado, Denver
• Solu-Cortef · Pfizer
• Vincristin · Arbeitsgemeinschaft medikamentoese Tumortherapie
• Valchlor · Recordati
  Valchlor works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death.
• Cortifoam · Pfizer
• Dtic-Dome · Bayer
• Gliadel · Avet Lifesciences
  Gliadel works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and grow.
• Blenoxane · Bristol-Myers Squibb
  Bleomycin works by binding to DNA and causing strand breaks, which ultimately leads to cell death.
• Cortone
• Celestone Soluspan
• Decadron · Generic (originally Merck)
• Brentuximab · University of Arizona
• adriacin · Chipscreen Biosciences, Ltd.
• Hydroxydaunorubicin · University of Colorado, Denver
• Cyclophosphamid · Zhejiang University
• Vinblastin · The Lymphoma Academic Research Organisation
• prednison · Wen Zhang
• Medrol · Generic (originally Upjohn/Pfizer)
  Potent synthetic glucocorticoid with 5x hydrocortisone potency and minimal mineralocorticoid activity, used for severe inflammatory conditions.
• Cortef · Generic (originally Merck/Upjohn)
• Gleostine · Azurity
  Gleostine works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death.
• Rodinolone
• Carmustin · University Hospital Freiburg
• Deltasone · Generic (originally Schering)
• Leukeran · Waylis
  Leukeran works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and ultimately leading to cell death.
• Cytoxan (Lyophilized) · Baxter
  Cyclophosphamide cross-links tumor cell DNA and interferes with malignant cell growth through active alkylating metabolites.
• Oncovin · Pfizer Inc.
• Oncovin · Pfizer Inc.
• Adcetris · Pfizer
  Adcetris works by binding to cancer cells that express CD30 and delivering a toxic payload to kill the cells.
• Liposomal Doxorubicin · Pfizer
• Matulane · Leadiant Biosci Inc
• Betametasone
  Betamethasone works by binding to the glucocorticoid receptor, which then triggers a series of downstream effects that reduce inflammation and suppress the immune system.
• Doxorubicin Hydrochloride · Pfizer
  Doxorubicin works by intercalating DNA strands and inhibiting topoisomerase II, an enzyme essential for DNA replication and cell division.
• Cytoxan (Lyophilized) · Baxter
  Cytoxan works by interfering with the DNA replication process in rapidly dividing cancer cells.
• Cortisol · University of Zurich
• Prelone · Generic (originally Schering)
• Hydroxydaunomycin · Weill Medical College of Cornell University
• prednisolon · Hannover Medical School
• Adriamycin · Johann Wolfgang Goethe University Hospital
• Methylprednisolon · Leiden University Medical Center

Clinical guidelines

• FDA label — any
  Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in Hodgkin's disease.
• FDA label — any
  Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in non-Hodgkin's malignant lymphomas.
• FDA label — any
  Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in rhabdomyosarcoma.
• FDA label — any
  Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in neuroblastoma.
• FDA label — any
  Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in Wilms' tumor.
• FDA label — 1L
  ADCETRIS is indicated for the treatment of adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine.
• FDA label — adjuvant
  ADCETRIS is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation.
• FDA label — 2L
  ADCETRIS is indicated for the treatment of adult patients with classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates.
• FDA label — 1L
  ADCETRIS is indicated for the treatment of adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified (NOS), in combination with cyclophosphamide, doxorubicin, and prednisone.
• FDA label — 2L
  ADCETRIS is indicated for the treatment of adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen.
• FDA label — 1L
  ADCETRIS is indicated for the treatment of pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide.
• FDA label — 2L
  ADCETRIS is indicated for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy.
• FDA label — 3L+
  ADCETRIS is indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell therapy, in combination with lenalidomide and a rituximab product.

Competitive intelligence

For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:

• Hodgkin's disease patent landscape — cliff calendar, originator estates, attackable patents
• Hodgkin's disease treatment landscape brief
• Hodgkin's disease treatment updates RSS

Frequently asked questions about Hodgkin's disease

Related

• Treatment landscape: Hodgkin's disease patent cliff · Hodgkin's disease CI report
• Treatment: Oncovin · University of Colorado, Denver
• Treatment: Solu-Cortef · Pfizer
• Treatment: Vincristin · Arbeitsgemeinschaft medikamentoese Tumortherapie
• Treatment: Valchlor · Recordati
• Treatment: Cortifoam · Pfizer
• All diseases: Browse the disease index · Disease landscape hub

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing